Featuring:

MALDI FT-ICR MS platform for proteomics: Rationale for an offline approach and optimised implementation
Eric Peters, Genomics Institute, Novartis Research Foundation

High content imaging subpopulation analysis for phenotypic drug discovery
Jonathan Low and Louis Stancato, Cancer Growth and Translational Genetics, Eli Lilly

Utilisation of secondary screening
Secondary Screening Roundtable

In vitro toxicity screening as pre-selection tool
Willem Schoonen, Walter Westerink and Jean Horbach, Department of Pharmacology, N.V. Organon, Schering-Plough Corporation

Platform technology for routine three dimensional cell culture
Stefan Pryborski, School of Biological Sciences, University of Durham

Peracetic acid in the study of rhIL-11 methionine oxidation
Nicholas Warne, Rebecca Koval and Thomas Crowley, Drug Product Development Group, Wyeth

SIEMENS: innovation, industry and implement
Ingrid Maes, Siemens Centre of Competence, Antwerp

Lyophilization: cycle robustness and process tolerances, transfer and scale up
Serguei Tchessalov and Nicholas Warne, Wyeth Biopharma, Andover

Wyeth's PAT variations submitted through the EMEA Worksharing Procedure
Graham Cook, Wyeth Manufacturing (UK) Ltd

Expo sets a new standard in PAT implementation
Paul Davies and Dr. Susan Bragg, Expo Technologies

MicroRNAs for high-throughput functional analysis
Holger Erfle, University of Heidelberg

Implementation, validation and registration of rapid microbiological methods
Paul Newby, Glaxosmithkline R&D, Ware, UK

PAT - reducing the cost of quality in consumer products manufacturing
Debbie Peru, Colgate Palmolive Co